Company intelligence / Profile preview

Gilva Therapeutics

Ownership: Private
Development stage: Other

Overview

Gilva Therapeutics is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for neurodegenerative diseases. Leveraging the research of Professor Ehud Gazit from Tel Aviv University, the company targets the early-stage aggregation of toxic proteins such as amyloid-beta, tau, and alpha-synuclein. Their approach aims to prevent the formation of toxic oligomers that lead to neuronal death in conditions like Alzheimer's and Parkinson's diseases. Gilva is backed by prominent life science investors including OrbiMed and Takeda Ventures.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

GV-100

Partnerships

Takeda VenturesJohnson & Johnson Innovation - JJDC

Beyond the preview

Go deeper on Gilva Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gilva Therapeutics.